Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases

Due to the low incidence of rare EGFR mutation, its response to EGFR-TKI has not been fully investigated. L747P is a rare EGFR mutation in EGFR exon 19. Previous case reports showed that patients with EGFR L747P mutation responded to afatinib treatment. However, we encountered a patient with EGFR L7...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yibin, Guo, Weixi, Jiang, Bin, Han, Chengkun, Ye, Feng, Wu, Jingxun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396254/
https://www.ncbi.nlm.nih.gov/pubmed/36016627
http://dx.doi.org/10.3389/fonc.2022.863771
_version_ 1784771889307058176
author Li, Yibin
Guo, Weixi
Jiang, Bin
Han, Chengkun
Ye, Feng
Wu, Jingxun
author_facet Li, Yibin
Guo, Weixi
Jiang, Bin
Han, Chengkun
Ye, Feng
Wu, Jingxun
author_sort Li, Yibin
collection PubMed
description Due to the low incidence of rare EGFR mutation, its response to EGFR-TKI has not been fully investigated. L747P is a rare EGFR mutation in EGFR exon 19. Previous case reports showed that patients with EGFR L747P mutation responded to afatinib treatment. However, we encountered a patient with EGFR L747P who was resistant to afatinib but responded to dacomitinib. It is the first case report of the effective application of dacomitinib in a patient with L747P mutation and BMS, and the efficacy of BMS achieved PR.
format Online
Article
Text
id pubmed-9396254
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93962542022-08-24 Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases Li, Yibin Guo, Weixi Jiang, Bin Han, Chengkun Ye, Feng Wu, Jingxun Front Oncol Oncology Due to the low incidence of rare EGFR mutation, its response to EGFR-TKI has not been fully investigated. L747P is a rare EGFR mutation in EGFR exon 19. Previous case reports showed that patients with EGFR L747P mutation responded to afatinib treatment. However, we encountered a patient with EGFR L747P who was resistant to afatinib but responded to dacomitinib. It is the first case report of the effective application of dacomitinib in a patient with L747P mutation and BMS, and the efficacy of BMS achieved PR. Frontiers Media S.A. 2022-08-09 /pmc/articles/PMC9396254/ /pubmed/36016627 http://dx.doi.org/10.3389/fonc.2022.863771 Text en Copyright © 2022 Li, Guo, Jiang, Han, Ye and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Yibin
Guo, Weixi
Jiang, Bin
Han, Chengkun
Ye, Feng
Wu, Jingxun
Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
title Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
title_full Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
title_fullStr Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
title_full_unstemmed Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
title_short Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
title_sort case report: dacomitinib is effective in lung adenocarcinoma with rare egfr mutation l747p and brain metastases
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396254/
https://www.ncbi.nlm.nih.gov/pubmed/36016627
http://dx.doi.org/10.3389/fonc.2022.863771
work_keys_str_mv AT liyibin casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases
AT guoweixi casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases
AT jiangbin casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases
AT hanchengkun casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases
AT yefeng casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases
AT wujingxun casereportdacomitinibiseffectiveinlungadenocarcinomawithrareegfrmutationl747pandbrainmetastases

Ejemplares similares